MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly launched trials. | Amgen’s most advanced obesity asset MariTide is entering ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...

MariTide only needs to be taken once a month, and it's helped people lose up to 20% of their weight. Shares of this biotech are priced at a much lower premium than top GLP-1 drugmaker Eli Lilly.

Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, the FDA cleared for ...

Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...

But MariTide, which is Amgen's GLP-1 drug, only needs to be taken once a month. That can make it easier to stay on top of treatments. It may also result in fewer side effects, which is a key ...